ArticleFrontiers in medicine2025
Risk prediction for recurrent pregnancy loss based on routine inspections in the first trimester of pregnancy, a retrospective study in China.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between homocysteine level and unexplained recurrent pregnancy loss: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Artificial Intelligence in Recurrent Pregnancy Loss: Current Evidence, Limitations, and Future Directions.Journal of clinical medicine · 2026Review
- A study of the association between the early pregnancy thrombosis-thyroid axis and pregnancy outcomes in patients with recurrent spontaneous abortion.Frontiers in endocrinology · 2026Article
- Uterine artery hemodynamic parameters as key predictors of missed abortion risk: clinical validation based on a multimodal predictive model.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent pregnancy loss (RPL) is one of the most common pregnancy complications in obstetrics and gynecology, and the incidence rate of RPL is about 2%. To establish a risk prediction model for recurrent pregnancy loss based on routine inspections in the first trimester of pregnancy. Materials and methods: A total of 3,010 women at Henan Provincial People's Hospital between January 2019 and December 2023. 810 women at Shangqiu Maternal and Child Health Hospital between January 2021 and April 2024. There were 523 women in the training set, 282 women in the testing set, and 229 women in the external validation set. Twelve routine inspections in the first trimester of pregnancy (4 ~ 12 weeks) were collected including thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine thyroid (FT4), thyroxine (TT4), total triiodothyronine (TT3), peroxidase antibody (TPO-Ab), thyroid globulin antibody (TG-Ab), 25-hydroxyvitamin D (25-(OH) D), ferritin (Ferr), Homocysteine (Hcy), vitamin B12 (VitB12), folic acid (FA). Logistic regression analysis was used to establish a risk prediction model based on training set. Receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were employed to evaluate the performance of prediction model on testing set and external validation set. Results: Chi-square test results for each single characteristic indicated that, TPO-Ab ( Conclusion: TPO-Ab, TG-Ab, 25-(OH) D, Hcy and FA may be closely related to the occurrence and development of RPL. The model only requires routine inspections in the first trimester of pregnancy to effectively indicate high-risk groups of RPL before the first miscarriage, making it convenient for clinical application and implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.